Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 9/20 | 1.00 |
| ▸ | CMA1 | P23946 | 4/20 | 1.00 |
| ▸ | MASP2 | O00187 | 1/20 | 0.89 |
| ▸ | ACP3 | P15309 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260969 | 1.00 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL30583367 | 1.00 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1614372 | 0.95 | CTSG (0.91) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL4455609 | 0.95 | CTSG (0.90) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL10146840 | 0.95 | CTSG (0.90) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1614715 | 0.94 | CTSG (0.89) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL4462315 | 0.94 | CTSG (0.89) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL31211813 | 0.94 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1613660 | 0.94 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL4456271 | 0.93 | CTSG (0.86) | CTSGCMA1MASP2ACP3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127908-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | claimed |
| WO-2025081091-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2024124212-A1 | DEVICES AND METHODS FOR DETECTION OF DISEASE BIOMARKERS AND THERAPEUTIC EFFECTIVENESS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-13 | — | — | WO | claimed |
| US-20250127908-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025081091-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025033330-A1 | ANTITUMOR THERAPY BY COMBINED USE OF CHYMASE INHIBITOR AND IMMUNOTHERAPY | 医療革新国際連携株式会社 | 2025-02-13 | — | — | WO | disclosed |
| CN-111655852-B | Aptamer for chymase and application thereof | 力博美科股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024124212-A1 | DEVICES AND METHODS FOR DETECTION OF DISEASE BIOMARKERS AND THERAPEUTIC EFFECTIVENESS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230313204-A1 | ANTI-CHYMASE APTAMER AND USE FOR SAME | RIBOMIC INC. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-11639503-B2 | Anti-chymase aptamer and use for same | RIBOMIC INC. (JP) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127908-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | BRDT, NFKBIA, SSB | CTSG 925/4885CMA1 2104/4885MASP2 2431/4885 |
| US-20230313204-A1 | ANTI-CHYMASE APTAMER AND USE FOR SAME | RNASE1, CPA1, RNASEH1 | CTSG 50/4885CMA1 4/4885MASP2 74/4885 |
| US-11639503-B2 | Anti-chymase aptamer and use for same | RNASE1, CPA1, RNASEH1 | CTSG 50/4885CMA1 4/4885MASP2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.